Yeruusaalem, 1 Sebtembar, 2026 (TPS-IL) — RedHill Biopharma, oo ah shirkad dawooyin gaar ah leh oo Israa’iili ah, ayaa waxay sheegtay Talaadadii inay heshay xuquuqda kaliya ee ganacsiga laba dawo oo ay FDA-du ansixisay oo lagu daweeyo xanuunnada caloosha iyo mindhicirada, kuwaas oo ka yimid shirkadda dawooyinka ee Swiss-ka ah ee Ferring Pharmaceuticals.
Heshiiskan oo dhan $12 milyan ah, RedHill waxay yeelan doontaa xuquuqda caalamiga ah ee Rebyota, oo ah dawo lagu joojiyo caabuqyada soo noqnoqonaya ee C. difficile, iyo xuquuqda Mareykanka ee Clenpiq, oo ah diyaargarow mindhicirka oo la isticmaalo ka hor baaritaanka colonoscopy. Laba badeecadood waxay soo xareeyeen qiyaastii $37.5 milyan oo iib ah oo ka dhacay Mareykanka sanadkii 2025, sida ay sheegtay RedHill.
Shirkaddu waxay sheegtay in helitaanka badeecadahaas lagu maalgeliyay iibka $18 milyan ee Talicia oo ay horey ugu dhawaaqday, kaas oo loo geeyay shirkadda dawooyinka ee Kanada ee Apotex, iyadoo la filayo inay jirto lacago dheeraad ah oo ku xidhan guulaha iyo boqolkiiba dakhliga.